STOK

26.7500.67%
AA

Arthur A. Levin

Independent Director

Dr. Arthur A. Levin, also known as Art, Ph.D, is Director of Marrow Therapeutics, Inc. Dr. Levin is Member of Strategic Advisory Board of Codexis, Inc. from February 2025. He served as Scientific Advisory Board of Atalanta Therapeutics, Inc. since 2024 until December 2025. He served as Director at Avidity Biosciences, Inc since February 2023 until February 27, 2026. and served as its Distinguished Scientist and Strategic Leader and Director since February 2023 and had been Chief Scientific Officer since January 2014 until February 2023 and as its Executive Vice President of Research and Development since October 2013 until October 2019. He served as Member of Scientific Advisory Board at Silence Therapeutics plc since February 2020. He is the Director of Comanche Biopharma Corp. He had been Independent Director at Ascidian Therapeutics, Inc. until 2025. Dr. Levin serves as an Independent Director of Stoke Therapeutics, Inc. since September 2015. Dr. Levin served as Executive Vice President of Research and Development at miRagen Therapeutics, Inc. since April 24, 2012 until January 2014. He has an unparalleled track record and reputation in the field of nucleic acid-based therapeutics. Dr. Levin has experience in the research and development of RNA-targeting therapeutics and three decades of experience in all aspects of drug development from discovery through drug registration, both in large pharma and biotech companies. Dr. Levin served as the Chief Development Officer, Vice President and President of US subsidiary of Santaris Pharma A/S Corporation. He has held senior drug development roles at ISIS Pharmaceuticals, Inc. and Santaris Pharma A/S Corporation. He has played key roles in the development of numerous of oligonucleotides including the first approved antisense NDAs and the first microRNA-targeted therapeutic in clinical trials. Prior to that, Dr. Levin held various senior management positions at Ionis Pharmaceuticals, Inc since September 2015. Dr. Levin served as a Senior Vice President of Development at Isis Pharmaceuticals, Inc., since January 2006, where he was responsible for the drug development of Isis' products across a range of therapeutic areas. He served as Senior Vice President of Preclinical Development at Isis Pharmaceuticals, Inc. He was instrumental in advancing more than a dozen antisense drugs from basic research to clinical development. Dr. Levin also held broad corporate responsibilities with Investors and corporate Partners. He served as Vice President of Development at Isis since 1995. He has managed more than countless preclinical programs at Isis Pharmaceuticals Inc., since 1995. Prior to Isis, he served at Hoffmann-La Roche Inc., where he served as a Research Leader in the Investigative Toxicology Department managing the Nuclear Receptor Research Group. During his tenure at Hoffman-LaRoche, he also established and supervised laboratories dedicated to the research of mechanisms of toxicity, biochemical toxicology and toxicokinetics. He served as a Member of Scientific Advisory Board at ProQR Therapeutics N.V. until 2024. He is a Director of the Oligonucleotide Therapeutics Society. He is a Diplomat of the American Board of Toxicology and a Member of The Society of Toxicology and The Teratology Society. He is an author of more than countless papers and book chapters. Dr. Levin has published over countless scientific articles and several of the most cited reviews in the field. He holds several additional scientific organization affiliations and honors. Dr. Levin was the recipient of the Scala Award for Industrial Toxicology. He received his Ph.D. in Toxicology from the University of Rochester School of Medicine and Dentistry, Rochester, New York and completed his Post-Doctoral work at the Chemical Industry Institute of Toxicology in Research Triangle, North Carolina. He holds a BS in Biology from Muhlenberg College.has B.S. in Biology from Muhlenberg College. Dr. Levin has Ph.D. in Toxicology from University of Rochester Medical Center.

Positions